MEXICOR [Emoxypine succinate]

Instructions for MEXICOR [Emoxypine succinate]

The pharmacological effect of the drug has a nootropic, anxiolytic, neuroprotective, antihypoxic, antioxidant effect on the human brain.

Release form:

caps. 100 mg: 20, 30 or 60 pcs
Description
Capsules are solid gelatine, size №2, yellow; the capsule contents are a granulate containing granules and a white or white powder with a yellowish tinge of colour.

1 cap.
ethylmethylhydroxypyridine succinate 100 mg
Auxiliary substances: potato starch - 54.5 mg, povidone (polyvinylpyrrolidone medical low molecular weight 12600±2700) - 4 mg, lactose (dairy sugar) - 40 mg, magnesium stearate - 0.5 mg, cellulose microcrystalline - 1 mg.

The composition of the capsule of solid gelatine №2: gelatin - 59.3189 mg, titanium dioxide (E171) - 1.22 mg, sunsetting dye yellow (E110) - 0.0036 mg, quinoline yellow dye (E104) - 0.4575 mg.

10 pcs - packages of box contour (2) - cardboard packs.
10 pcs - box-type contour (3) packages - cardboard packs.
10 pcs - packages of box contour (6) - cardboard packs.

ATC codes
C01EB Other drugs MEXICOR for heart disease

N07XX Other drugs for the treatment of diseases of the nervous system

Clinical-pharmacological groups / Group affiliation
Antioxidant preparation

Active substance:

ethylmethylhydroxypyridine succinate

Pharmacotherapy group:

Antioxidant agent

Storage Conditions
The drug MEXICOR should be stored in a place inaccessible to children, dry, protected from light at a temperature not higher than 25 ° C.

Best before date
Shelf life is 3 years.

Pharmacological effect
Pharmacodynamics

Antioxidant drug MEXICOR.

Ethylmethylhydroxypyridine succinate has antioxidant, antihypoxic, antiischemic, membrane protective, nootropic, stress-protective, anticonvulsant, anxiolytic effects.

The preparation promotes the body's resistance to various damaging factors, in case of oxygen-dependent pathological conditions (shock, hypoxia and ischemia, disorders of cerebral circulation, IBS, ethanol intoxication and post-intoxication by antipsychotic agents). The preparation reduces manifestations of oxidative stress, inhibits free-radical processes of lipid peroxidation, and increases the activity of superoxide dismutase. Modulates the activity of membrane-bound enzymes such as calcium-independent PDE, adenylate cyclase, acetylcholinesterase and receptor complexes (benzodiazepine, gamma-aminobutyric, acetylcholine), which enhance their binding capacity to ligands, helps preserve the structural-functional organization of biological membranes, and improves neurotransmitter transport and synaptic transmission. Increases dopamine content in the brain.

The preparation causes an increase in the compensatory activity of aerobic glycolysis and contributes to a reduction in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxia conditions, with an increase in the content of adenosine triphosphate, creatinphosphate and activation of the energy-synthesizing functions of mitochondria, and stabilization of cell membranes.

In patients with stable angina strain, it increases tolerance to physical activity and antianginal activity of nitropreparations, improves rheological properties of blood. The addition of MEXICOR® to standard IBS therapy improves the clinical condition of patients, increasing tolerance to exercise and improving quality of life.

In patients with stable strain angina, the patient increases tolerance to physical strain and anti-anginal activity of nitropreparations, improves the rheological properties of the blood, reduces platelet aggregation and the consequences of reperfusion syndrome in cases of acute coronary insufficiency. It has a hypolipidemic effect and reduces total cholesterol and LDL.

Improves cerebral blood supply and cerebral metabolism, improves blood microcirculation, prevents a decrease in cerebral blood flow in the reperfusion period after ischemia. Prevents the brain from post-traumatic loss of glucose and oxygen utilization, and prevents progressive lactate accumulation. The preparation has a selective, non-sedative and muscle relaxation, anxiolytic effect, eliminates anxiety, fear, tension, anxiety, increases adaptation and emotional status.

The effectiveness of the preparation in the conditions of stress effects is manifested in the normalization of post-stress behavior, psycho-vegetative disorders, the restoration of sleep-wake cycles, mnestic functions, learning processes, and the reduction of structural changes in brain matter. The preparation is characterized by a marked antitoxic effect in withdrawal syndrome. It eliminates neurological manifestations of acute alcohol intoxication, restores behavioral disorders, vegetative function, and reduces cognitive impairment caused by prolonged ethanol intake. Under the influence of ethylmethylhydroxypyridine succinate, the action of tranquilizing, neuroleptic, antidepressant, sleeping pills and anticonvulsant drugs MEXICOR is enhanced, which allows to reduce their doses and reduce side effects.

Testimony:

IBS (as part of complex therapy);
Consequences of acute disorders of cerebral circulation/
D including after transient ischemic attacks, in the phase of subcompensation, as preventive courses;
Mild traumatic brain injury and consequences of traumatic brain injury.
Encephalopathy of various genesis (dyscirculatory, dysmetabolic, post-traumatic, mixed);
functional disorders of the autonomic nervous system (syndrome of vegetative-free dystonia);
mild cognitive disorders of atherosclerotic genesis;
anxiety disorders in neurotic and neurotic conditions;
Withdrawal syndrome in alcoholism with a predominance of neurotic and vegetative vascular disorders, post-withdrawal disorders;
Acute intoxication with antipsychotics;
Various asthenic conditions, as well as for the prevention of the development of somatic diseases under the influence of extreme factors and loads;
Impact of extreme (stressors) factors.

Method of use and doses:

B/m or B/W (jet or drip).
In the treatment of acute myocardial infarction, administration is carried out in/in or in/out for 14 days against the background of a traditional myocardial infarction therapy comprising nitrates, β-adrenolocators, ACE inhibitors, thrombolytics, anticoagulants and antiaggregants, as well as symptom-based means.
In the first 5 days, to achieve the maximum effect, the drug is desirable to be administered in / in, in the subsequent 9 days - in / m.
The preparation is administered in a slow drip infusion (in order to avoid side effects) on a physiological solution or a 5% solution of dextrose (glucose) in a volume of 100-150 ml for 30-90 min. If necessary, a slow jet injection of the preparation, lasting at least 5 minutes, is possible.
The preparation is administered (b/v or b/m) 3 times a day, and a daily therapeutic dose of 6-9 mg/kg/day is administered every 8 Days and a one-time dose of 2-3 mg/kg. The maximum daily dose shall not exceed 800 mg, a single dose of 250 mg.
For acute disorders of cerebral circulation (ischemic stroke) MEXICOR is used in complex therapy in the first 2-4 days in / in, drip 200-300 mg 2-3 times a day, then - in / m 100 mg 3 times a day. The duration of treatment is 10-14 days. The drug is then given in 100 mg capsules twice daily for 14 days and 100 mg three times daily for the next 7 days. The frequency and duration of repeated therapy is determined by the doctor.
In the discirculatory encephalopathy phase of discompensation, Mexicor should be given in/out of the stream or drip in a dose of 100 mg 2-3 times per day for 14 days. The preparation is then administered in a/m dose of 100 mg per day over the next 2 weeks. In the future, the drug is prescribed in capsules of 100 mg 2-4 times a day (on the recommendation of the doctor), the frequency and duration of the therapy courses MEXICOR is determined by the doctor.
For the course-based prophylaxis of the discirculatory encephalopathy, the preparation is administered in/m in a dose of 100 mg twice daily for a period of 10-14 days

Overdose:

Due to the low toxicity of the drug, overdose is unlikely. There is no information on overdose cases.
Symptoms: Overdose may cause symptoms of sleep disturbance - drowsiness, insomnia.
Treatment: They perform symptomatic therapy.
Use in pregnancy and breastfeeding

The use of MEXICOR® is contraindicated in pregnancy (there is no clinical evidence of the drug in pregnant women) and during breastfeeding. Breastfeeding should be stopped before taking the drug MEXICOR.

Side Effect:

Possible: allergic reactions (including systemic allergic reactions), dyspeptic phenomena (nausea, dry mouth, diarrhea), which quickly disappear on their own or when the drug MEXICOR is cancelled.

For long-term use: There may be flatulence, sleep disturbances (drowsiness or sleep disturbance).

Contraindications for use:

increased sensitivity to the active substance or other components of the preparation;
acute liver failure;
acute renal failure;
Children under 18 years of age (safety and efficacy of the drug MEXICOR in children not studied);
pregnancy;
Breastfeeding period;
Rare hereditary galactosis intolerance, lactase deficiency, glucose-galactosis malabsorption syndrome (the drug contains lactose).
With caution: liver dysfunction, kidney dysfunction (limited medical experience).

Special Instructions:

In patients with kidney or liver dysfunction, the drug MEXICOR should be used with caution, conducting periodic monitoring of kidney and liver function.

Due to the presence of lactose in the composition of the drug MEXICOR®, the use of the preparation is contraindicated in patients with rare hereditary intolerance of galactosis, lactase deficiency, glucose-galactosis malabsorption.

The preparation in the composition of auxiliary substances contains dyes and can be the cause of the development of allergic reactions (including systemic). If there are signs of an allergic reaction, the use of the drug should be stopped immediately.

Impact on the ability to drive vehicles and machinery

During treatment with the drug MEXICOR, care must be taken when driving a motor vehicle and engaging in other potentially dangerous activities requiring increased concentration of attention and rapid psychomotor reactions.

Use in children
Contraindication: Children and adolescents under 18 years of age (effectiveness and safety are not established).

interaction
Do anticonvulsants (carbamazepine), protivoparkinsonichesky funds (levodopa) and benzodiazepine anxiolytics.
Increases antianginalnal activity nitropreparatov.

Nosology (ICD codes)
F07
Personality and behavioural disorders caused by disease, damage or brain dysfunction
F10.3
Withdrawal state
F40
Phobic anxiety disorders (including agoraphobia, social phobias)
F41.8
Other specified anxiety disorders
F43
Response to severe stress and adaptation disorders
F45.3
Somatoform dysfunction of the autonomic nervous system
F48.0
Neurasthenia
G45
Transitory cerebral ischemic attacks [attacks] and related syndromes
G92
Toxic encephalopathy
G93.4
Encephalopathy unrefined
I20
Angina [breast toad]
I61
Intracerebral hemorrhage (haemorrhagic type disorder)
I63
Brain infarction
I67.2
Cerebral atherosclerosis
I67.4
Hypertensive encephalopathy
I69
Effects of cerebrovascular disease
R53
Malaise and fatigue
S06
Intracranial injury
T43.3
Antipsychotic and neuroleptic drugs
T90
Effects of head injuries
Z73.0
Overwork
Z73.3
Stress conditions not classified in other headings (physical and mental stress)